Welcome to Pfizer’s News & Media Center—designed to give you immediate access to timely and relevant information about our company. In this section you will find information and resources for journalists, including current and archived Pfizer press releases, a full company press kit, and a comprehensive collection of images and videos in our multimedia library.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Tuesday, June 2, 2015 at 4:30 p.m. EDT. The purpose of the call is to provide an update on Pfizer’s oncology business and to review Pfizer’s ASCO data presentations.
Pfizer Inc. (NYSE:PFE) today announced that it has received a request for additional information from the U.S. Federal Trade Commission (“FTC”) with respect to its previously announced proposed acquisition of Hospira. The request for information from the FTC, often referred to as a “second request,” was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”).
Pfizer Inc. today announced that Director Marc Tessier-Lavigne, Ph.D. has decided to step down from its Board of Directors on May 14, 2015. His decision is coincident with the launch of Denali, a new biotechnology company focused on developing effective therapies for neurodegenerative diseases. Dr. Tessier-Lavigne is a co-founder of Denali, and he will serve as the chairman of the company.
Merck KGaA, Darmstadt, Germany, and Pfizer today announced multiple presentations on studies evaluating the preliminary safety and efficacy of avelumab* at the 2015 American Society of Clinical Oncology (ASCO) annual meeting.
AM‐Pharma B.V., a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, and Pfizer Inc. (NYSE:PFE) announced today that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company.
Pfizer Inc. announced today two strategic appointments in the leadership of the Worldwide Research and Development organization effective immediately. Michael D. Ehlers, M.D., Ph.D., has been selected as Group Senior Vice President and Head of BioTherapeutics Research & Development and Site Head for Pfizer’s Cambridge and Boston, Massachusetts locations.
Teleconference: Prevenar 13
Pfizer signs long-term agreement to supply Prevenar 13 to world's poorest countries.
Access the Pfizer Presentation Archive to view Executive Leadership presentations to shareholders, analysts, and global health care conferences.
Executive Speeches & Commentary
View Executive Leadership speeches on a variety of topics.
Pfizer Twitter Community
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
Current Stock Price
|%Change||.||52 Wk. High||.|
|Day High||.||52 Wk. Low||.|
|Day Low||.||Mkt. Cap(Mil)||.|
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.